New Potential Agents for Malignant Melanoma Treatment—Most Recent Studies 2020–2022

Kozyra, Paweł; Krasowska, Danuta; Pitucha, Monika

doi:10.3390/ijms23116084

Cited by 14 publications

(8 citation statements)

References 149 publications

(198 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Prior to this study, very little was known about whether extracts of Sinningia plants can suppress the growth of cancer cells. Malignant melanoma is the most dangerous and the most common type of skin cancer [ 26 ]. Considering that many natural products exhibit anticancer properties towards skin cancers, the highly metastatic B16F10 melanoma cells were selected for this investigation.…”

Section: Resultsmentioning

confidence: 99%

Cytotoxic, Antibacterial, and Antioxidant Activities of the Leaf Extract of Sinningia bullata

Chen

Lin

et al. 2023

Plants

View full text Add to dashboard Cite

Sinningia bullata is a tuberous member of the flowering plant family Gesneriaceae. Prior to this work, the antibacterial, antioxidant, and cytotoxic properties of S. bullata were undetermined. Here, we prepared different extracts from the leaf, stem, and tuber of S. bullata and investigated their pharmacological activities. The leaf extract of S. bullata, obtained by 100% acetone (Sb-L-A), had the highest total flavonoid content, antioxidation capacity, and cytotoxic and antibacterial activities. Sb-L-A displayed a broad range of antibacterial activities against Escherichia coli, Staphylococcus aureus, and Pseudomonas aeruginosa. The inhibition zones of Sb-L-A ranged from 8 to 30 mm and were in the following order: S. aureus > E. coli > P. aeruginosa. Incubation of B16F10 melanoma cells with Sb-L-A at a concentration of 80 μg/mL caused deaths at the rate of 96%, reduced migration by 100%, suppressed proliferation and colony formation by 99%, and induced apoptosis, which was observed in 96% of the B16F10 cells. In addition, the cytotoxic activities of Sb-L-A were synergistically enhanced when coacting with the antitumor drug epothilone B. Sb-L-A was also used to determine the cytotoxic effects against 4T1 mammary carcinoma cells. Sb-L-A of 60 μg/mL boosted the distribution of the G2 phase from 1.4% to 24.4% in the B16F10 cells. Accordingly, Sb-L-A might suppress melanoma cell proliferation by inducing G2 cell-cycle arrest. The most abundant compounds in Sb-L-A were identified using gas chromatography–mass spectrometry. The top two contents in this extract were adlupulone and villosin. Overall, the collective data in this study may indicate the pharmacological potentials of Sb-L-A for possible medical applications.

show abstract

Section: Resultsmentioning

confidence: 99%

Cytotoxic, Antibacterial, and Antioxidant Activities of the Leaf Extract of Sinningia bullata

Chen

Lin

et al. 2023

Plants

View full text Add to dashboard Cite

show abstract

“…Compounds containing phthalimide moieties have been observed to have potential anti-tumor activity. 22–24 Moreover, cyclic peptides exhibit more stable chemical properties than linear cyclic peptides in a variety of chemical and biological environments, and thus have better pharmacological properties. Therefore, the cytotoxicity of all synthesized linear peptide precursors ( 1a–14a ) and cyclic peptides ( 1–14 , Scheme 1) was assessed.…”

Section: Resultsmentioning

confidence: 99%

Photo-induced synthesis, stereochemistry and antitumor activity of valine-based small cyclopeptides

Bao

Zhang

et al. 2023

New J. Chem.

View full text Add to dashboard Cite

show abstract

“…Given the upregulated nature of this process as a result of proliferation, DHODH inhibitors represent a new hope for targeted therapy for melanoma [ 94 ]. Our review of the literature on the latest anti-melanoma agents revealed that the phenoxy derivatives we have obtained are among the first in recent years [ 95 ]. The most active compound bore a 2-iodophenyl substituent [ 93 ].…”

Section: Novel Agent With the Terminal Phenoxy Group From The Most Re...mentioning

confidence: 99%

Terminal Phenoxy Group as a Privileged Moiety of the Drug Scaffold—A Short Review of Most Recent Studies 2013–2022

Kozyra

Pitucha

2022

IJMS

Self Cite

View full text Add to dashboard Cite

The terminal phenoxy group is a moiety of many drugs in use today. Numerous literature reports indicated its crucial importance for biological activity; thus, it is a privileged scaffold in medicinal chemistry. This review focuses on the latest achievements in the field of novel potential agents bearing a terminal phenoxy group in 2013–2022. The article provided information on neurological, anticancer, potential lymphoma agent, anti-HIV, antimicrobial, antiparasitic, analgesic, anti-diabetic as well as larvicidal, cholesterol esterase inhibitors, and antithrombotic or agonistic activities towards the adrenergic receptor. Additionally, for selected agents, the Structure–Activity–Relationship (SAR) is also discussed. Thus, this study may help the readers to better understand the nature of the phenoxy group, which will translate into rational drug design and the development of a more efficient drug. To the best of our knowledge, this is the first review devoted to an in-depth analysis of the various activities of compounds bearing terminal phenoxy moiety.

show abstract

New Potential Agents for Malignant Melanoma Treatment—Most Recent Studies 2020–2022

Cited by 14 publications

References 149 publications

Cytotoxic, Antibacterial, and Antioxidant Activities of the Leaf Extract of Sinningia bullata

Cytotoxic, Antibacterial, and Antioxidant Activities of the Leaf Extract of Sinningia bullata

Photo-induced synthesis, stereochemistry and antitumor activity of valine-based small cyclopeptides

Terminal Phenoxy Group as a Privileged Moiety of the Drug Scaffold—A Short Review of Most Recent Studies 2013–2022

Contact Info

Product

Resources

About